Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 126

1.

On the Application of a Diffusive Memristor Compact Model to Neuromorphic Circuits.

Cisternas Ferri A, Rapoport A, Fierens PI, Patterson GA, Miranda E, Suñé J.

Materials (Basel). 2019 Jul 13;12(14). pii: E2260. doi: 10.3390/ma12142260.

2.

Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications.

Rapoport AM, Bonner JH, Lin T, Harris D, Gruper Y, Ironi A, Cowan RP.

J Headache Pain. 2019 Jul 22;20(1):83. doi: 10.1186/s10194-019-1033-9.

3.

Fremanezumab as a preventive treatment for episodic and chronic migraine.

Bigal ME, Walter S, Rapoport AM.

Expert Rev Neurother. 2019 Aug;19(8):719-728. doi: 10.1080/14737175.2019.1614742. Epub 2019 May 22.

PMID:
31043094
4.

The American Headache Society's Position Statement on Integrating New Migraine Treatments into Clinical Practice - Comments.

Charles JA, Rapoport AM.

Headache. 2019 Apr;59(4):629. doi: 10.1111/head.13496. No abstract available. Erratum in: Headache. 2019 Jul;59(7):1129.

PMID:
30973200
5.

Migraine and episodic Vertigo: a cohort survey study of their relationship.

Lampl C, Rapoport A, Levin M, Bräutigam E.

J Headache Pain. 2019 Apr 8;20(1):33. doi: 10.1186/s10194-019-0991-2.

6.

Some aspects on the pathophysiology of migraine and a review of device therapies for migraine and cluster headache.

Rapoport AM, Edvinsson L.

Neurol Sci. 2019 May;40(Suppl 1):75-80. doi: 10.1007/s10072-019-03828-0. Review.

PMID:
30906962
8.

The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment.

Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME.

Headache. 2019 Mar;59(3):383-393. doi: 10.1111/head.13446. Epub 2018 Nov 18.

PMID:
30450545
9.

The Headache Cooperative of New England (HCNE) Symposium on Calcitonin Gene-Related Peptide.

Rapoport AM.

Headache. 2018 Nov;58 Suppl 3:217. doi: 10.1111/head.13410. No abstract available.

PMID:
30403406
10.

From LBR-101 to Fremanezumab for Migraine.

Bigal ME, Rapoport AM, Silberstein SD, Walter S, Hargreaves RJ, Aycardi E.

CNS Drugs. 2018 Nov;32(11):1025-1037. doi: 10.1007/s40263-018-0579-4. Review.

PMID:
30311143
11.

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study.

Landy S, Munjal S, Brand-Schieber E, Rapoport AM.

J Headache Pain. 2018 Aug 15;19(1):69. doi: 10.1186/s10194-018-0881-z.

12.

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study.

Landy S, Munjal S, Brand-Schieber E, Rapoport AM.

J Headache Pain. 2018 Aug 15;19(1):70. doi: 10.1186/s10194-018-0882-y.

13.

A new era in headache treatment.

Vikelis M, Spingos KC, Rapoport AM.

Neurol Sci. 2018 Jun;39(Suppl 1):47-58. doi: 10.1007/s10072-018-3337-y. Review.

PMID:
29904827
14.

DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.

Lipton RB, Munjal S, Brand-Schieber E, Rapoport AM.

Headache. 2018 May;58(5):676-687. doi: 10.1111/head.13309.

PMID:
29878341
15.

CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.

Maasumi K, Michael RL, Rapoport AM.

Drugs. 2018 Jun;78(9):913-928. doi: 10.1007/s40265-018-0923-5. Review.

PMID:
29869205
16.

Experts' opinion about the pediatric secondary headaches diagnostic criteria of the ICHD-3 beta.

Özge A, Abu-Arafeh I, Gelfand AA, Goadsby PJ, Cuvellier JC, Valeriani M, Sergeev A, Barlow K, Uludüz D, Yalın OÖ, Faedda N, Lipton RB, Rapoport A, Guidetti V.

J Headache Pain. 2017 Nov 29;18(1):113. doi: 10.1186/s10194-017-0819-x.

17.

Experts' opinion about the primary headache diagnostic criteria of the ICHD-3rd edition beta in children and adolescents.

Özge A, Faedda N, Abu-Arafeh I, Gelfand AA, Goadsby PJ, Cuvellier JC, Valeriani M, Sergeev A, Barlow K, Uludüz D, Yalın OÖ, Lipton RB, Rapoport A, Guidetti V.

J Headache Pain. 2017 Nov 23;18(1):109. doi: 10.1186/s10194-017-0818-y. Review.

18.

The emerging role of gammaCore® in the management of cluster headache: expert panel recommendations.

Silberstein SD, Calhoun AH, Treppendahl C, Dodick DW, Rapoport AM, Mamidi A, Vargas P, Ebert TH, Tepper SJ.

Am J Manag Care. 2017 Nov;23(17 Suppl):S326-S333.

19.

Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.

Schuster NM, Rapoport AM.

Clin Neuropharmacol. 2017 Jul/Aug;40(4):169-174. doi: 10.1097/WNF.0000000000000227. Review.

PMID:
28644160
20.

New treatments for headache.

Maasumi K, Tepper SJ, Rapoport AM.

Neurol Sci. 2017 May;38(Suppl 1):145-156. doi: 10.1007/s10072-017-2910-0. Review.

PMID:
28527051

Supplemental Content

Loading ...
Support Center